AAAmani M. Ali

Amani M. Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amani M. Ali has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of Plasmapheresis on Serum Concentrations of Antiseizure Medications: A Systematic Review

    by Eman A. Makhlouf, Salma M. Abdel Fattah, Noha T. Abokrysha, Amani M. Ali

    Seizures are an important neurological manifestation of several autoimmune and antibody‐mediated disorders and often require treatment with antiseizure medications (ASMs). Therapeutic plasma exchange (TPE) is frequently used to treat these antibody‐mediated conditions by removing circulating pathogenic factors. However, TPE is non‐selective and may also remove protein‐bound ASMs, particularly those with low volume of distribution. This unintended drug clearance may result in subtherapeutic concentrations and breakthrough seizures. This study aims to systematically assess the available evidence on the effects of TPE on ASM serum concentrations. It also seeks to determine whether drug removal is clinically significant and needs post‐procedure supplemental dosing. A systematic literature search was conducted in PubMed, Web of Science, Scopus, and Cochrane Library from April to May 2025 using predefined MeSH terms and keywords related to epilepsy, ASMs, and TPE. Randomized trials and case reports/series involving patients receiving ASMs concomitantly with TPE and reporting serum drug concentrations were included. Two independent reviewers performed study selection, data extraction, and quality assessment using the Joanna Briggs Institute checklist, in accordance with PRISMA guidelines. The primary outcome was the effect of TPE on ASM serum concentrations and the need for dose adjustment. Eighteen studies comprising 30 patients were included. Phenytoin was the most frequently evaluated ASM; although total serum concentrations often declined during TPE, overall drug removal was generally low, and free levels frequently remained therapeutic. Phenobarbital showed minimal change, while valproate and several newer ASMs demonstrated variable reductions in serum concentrations. Breakthrough seizures were reported in seven studies, ranging from transient events to refractory seizures requiring dose adjustments or treatment discontinuation. The effect of TPE on ASM pharmacokinetics was found to be drug‐specific and largely influenced by protein binding and volume of distribution. Although overall drug removal is generally limited, peri‐procedural serum fluctuations may contribute to breakthrough seizures in vulnerable patients. Routine supplemental dosing is not generally recommended; instead, individualized monitoring, and post‐session dosing strategies are advised, particularly for ASMs with low volume of distribution or in high‐risk patients.

  • Open Access

    Evaluating large language models for pharmacotherapy simulations: a mixed-methods study

    by Ahmed N. Farrag, Amany El-Zeiny, Amani M. Ali

    Simulation-based learning is essential in clinical pharmacy education but requires substantial faculty resources that limit scalability. Large language models (LLMs) offer promise for generating scalable simulations, yet their pedagogical rigor and clinical reliability remain unclear. In a mixed-methods, counterbalanced evaluation study, PharmD students ( n = 104) engaged with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) cases, conditions requiring complex longitudinal management yet sharing semantic similarity, generated by four LLMs using expert-guided meta-prompts. Expert panels evaluated sessions across clinical authenticity, instructional design, and clinical reasoning; students completed satisfaction surveys. Of 103 sessions, 53 (51.5%) met passing criteria across all domains. Clinical accuracy and safety emerged as the limiting domain (58.3%) compared to clinical reasoning (81.6%) and instructional design (82.5%). CML sessions outperformed AML sessions (62.3% vs 40.0%; p = 0.031). Platform success rates ranged from 34.5% to 62.1%. Error analysis revealed guideline misalignment, pharmacotherapeutic inaccuracies, fabricated evidence, and cross-condition therapeutic recommendations occurring exclusively in AML sessions. Students favored LLMs over traditional methods (49.8% vs 30.0%); however, we did not detect statistically significant alignment between student satisfaction and expert-assessed quality. Sessions more frequently met criteria for instructional design and clinical reasoning than for pharmacotherapeutic accuracy and guideline alignment. Expert oversight with platform-specific and disease-specific validation remains essential for safe educational deployment, and effectiveness trials assessing objective learning outcomes represent necessary subsequent work.


  • Open Access

    Clinical pharmacists’ interventions, resistance, and training needs in ICUs: a FASTHUG-MAIDENS cross-sectional study

    by Amani M. Ali, Asia S. Toukhy, Salwa S. Abougalambou

    Introduction: To standardize and optimize daily patient assessment, many intensive care unit (ICU) clinical pharmacists worldwide have adopted FASTHUG-MAIDENS, a comprehensive mnemonic that guides systematic evaluation of essential care domains, including Feeding, Analgesia, Sedation, Thromboprophylaxis, Hyper/hypoactive delirium, Ulcer prophylaxis, Glucose control, Medication reconciliation, Antibiotics, Indications for medications, Drug dosing, Electrolytes, No drug interactions/allergies, and Stop dates. However, despite its recognized value, pharmacists may still encounter interprofessional resistance and face training gaps that hinder optimal patient care. Aim: The objective of this study was to evaluate the key areas of ICU clinical pharmacist interventions, identify interprofessional resistance, and explore training needs within the context of the FASTHUG-MAIDENS checklist. Methods: A cross-sectional survey was conducted in December 2024 using a self-administered online questionnaire distributed to ICU clinical pharmacists across Egypt. Descriptive statistics and Kendall’s tau-b correlation test were used to analyze the data, with a p -value < 0.05 considered significant. Results: Of the 121 ICU clinical pharmacists surveyed, most were female (76%), under 35 years of age, and working in public hospitals, with nearly two-thirds having less than five years of experience. Across all 14 mnemonic components, interprofessional resistance was most frequently encountered in sedation, antimicrobial therapy, medication indication, and stop-date domains. The highest reported training needs were in feeding, sedation, and delirium management. A significant positive correlation was observed between perceived training needs and the frequency of encountering resistance (r = 0.655, p < 0.001). Conclusion: Targeted education, particularly in sedation, delirium management, and nutrition, combined with strategies to address interprofessional barriers is essential to maximize pharmacists’ impact on patient care.

  • Open Access

    Medication reconciliation in clinical practice: a survey of knowledge, attitude, and practices among Egyptian healthcare providers

    by Aya M. AbdelMagid, Nirmeen A. Sabry, Ahmed Abuelhana, Aaron Courtenay, Amani M. Ali

    Background: Patients are at significant risk of harm from unintended medication errors, which remain prevalent and often preventable in healthcare systems, especially in low- and middle-income countries. Medication reconciliation (MedRec) plays a critical role in minimizing these errors by ensuring an accurate and complete medication list throughout patient transitions in the healthcare system. Aim: This study aimed to assess the current status of the MedRec process in Egypt by exploring the knowledge, attitudes, and practices of physicians and pharmacists as key stakeholders in its implementation. Methods: This descriptive, cross-sectional study used a structured, validated, self-administered online questionnaire targeting Egyptian physicians and pharmacists. The questionnaire was distributed via snowball sampling through professional networks and social media. Branching logic was used to tailor questions based on respondents’ familiarity with MedRec and hospital-based practices. Descriptive statistics were used to summarize the responses, while Chi-square and Mann–Whitney U tests were used to assess group differences. Results: Among 272 respondents (182 pharmacists, 90 physicians), representing multiple Egyptian governorates and healthcare sectors (public, private, and military). Among them, 66.9% reported familiarity with MedRec, significantly higher among pharmacists (73.1% vs. 54.4%; p = 0.002). Most respondents (70.2%) rated MedRec as “very valuable” for patient safety, and both groups expressed strong responsibility for its core tasks. Among the 136 hospital-based respondents familiar with MedRec, 79.4% reported institutional implementation. Physicians were more likely than pharmacists to ask patients for their current medication lists (93.8% vs. 76.1%; p = 0.021). Sources of medication history included patient lists or physician documents (74.3%), family interviews (74.3%), medication boxes from home (59.56%), discharge orders (52.2%), and transfer orders from other facilities (33.8%). Conclusion: Continuous education and training programs are required to close knowledge gaps, strengthen MedRec practices, and promote a culture of patient safety in Egypt.

  • Open Access

    Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis

    by Amani M. Ali, Mohamed E. Abdelrahim, Aya M. AbdelMagid

    Background: Autoimmune hepatitis (AIH) is a chronic progressive inflammatory liver disease of immune-mediated origin, which causes long-term liver inflammation and damage. Traditionally, treatment includes azathioprine (AZA) combined with steroids, but recent studies have highlighted mycophenolate mofetil (MMF) as a potential alternative, particularly for patients who do not respond well to AZA. Aims: This study aimed to evaluate the efficacy and safety of MMF versus AZA combined with steroids as first-line treatment for the management of AIH patients. Methods: A comprehensive systematic review was conducted using the keywords: mycophenolate mofetil, Cellcept, and autoimmune hepatitis. Studies comparing MMF to AZA combined with steroids in treatment-naïve patients with AIH were included. Efficacy was assessed based on complete biochemical remission (CBR), non-response, and relapse rates. Safety was evaluated on the basis of the incidence of serious adverse effects that led to treatment discontinuation. Statistical analysis included calculation of odds ratios (OR) and 95% confidence intervals (CI). Results: Out of 344 search results, four studies met the inclusion criteria, encompassing a total of 512 patients. MMF combined with prednisolone significantly improved both short-term CBR rates (OR, 2.56; 95% CI, 1.18–5.55) and long-term CBR rates (OR, 5.51; 95% CI, 1.7–17.91) compared to AZA combined with prednisolone. Furthermore, MMF treatment was associated with a significantly lower occurrence of serious adverse events (OR, 0.15; 95% CI, 0.07–0.34). Conclusions: Compared to AZA-based regimens, MMF-based first-line therapy for AIH appears to be a more promising, effective, and safe treatment option, yielding higher CBR rates and fewer serious adverse events requiring treatment discontinuation.


  • Open Access

    A Cost Variation Analysis of Drugs Available for the Treatment of Hypothyroidism in the Egyptian Market

    by Nourhanne M. El-Sebaey, Amani M. Ali, Samar F. Farid

    Background: A sizable portion of each nation's overall healthcare costs is being spent on pharmaceutical products. Hence, alternative and competing healthcare strategies or multiple brands of a specific prescription must be prioritized, especially in the case of chronic illnesses for countries with limited resources. That is why we conducted this analysis to start a series of cost variation analyses to help decision-makers, healthcare insurers, and even physicians to be well-informed and aware of the cost variation of available treatment options for optimal selection of the most convenient alternative. Objective: This analysis was conducted to determine the cost variation among levothyroxine options for hypothyroidism treatment currently available in the Egyptian market. Methodology: Ten alternatives of levothyroxine (25, 50, 100 mcg) were identified, and the corresponding prices were derived from the Egyptian Drug Authority Database. Different cost analyses were conducted through Microsoft Excel software. Results: The maximum retail cost per tablet that was observed in the branded levothyroxine 100 mcg is 0.70 EGP, while the minimum retail cost per tablet that was observed in levothyroxine 100 mcg generic medications is 0.11 EGP. The maximum cost ratio was observed between levothyroxine 100 mcg medications and was estimated at 6.364. The highest percent cost variation of 536.36% was noticed in levothyroxine 100 mcg medications compared to the percent cost variation of levothyroxine 50 mcg medications. The generic alternatives of levothyroxine 50 mcg have recorded a cost variation of 0%. Conclusion: There is a wide variation in pricing amongst generic levothyroxine in both concentrations compared to branded levothyroxine.

  • Open Access

    The effect of vitamin K4 supplementation on insulin resistance in individuals with type 2 diabetes: a double-blind randomised placebo-controlled clinical trial

    by Amani M. Ali, Maggie M. Abbassi, Nirmeen A. Sabry, May Fawzi, Shrook Mousa

    Purpose: The purpose of this study was to assess the possible clinical effects of vitamin K4 supplementation in individuals with type 2 diabetes namely insulin resistance, glycaemic control, and lipid profile. Methods: This was a prospective randomised double-blind placebo-controlled clinical trial. A total of 106 patients were randomised to receive either 1 mg of vitamin K4 (menadiol diacetate) or placebo for 24 weeks. Results: Ninety patients (n = 45 in each study group) were included in the final analysis. After 24 weeks, homeostatic model assessment of insulin resistance (HOMA-IR) (16.54 ± 7.81 vs. 29.09 ± 36.56, P = 0.027) and fasting serum insulin (FSI) (6.86 ± 3.45 vs. 11.13 ± 12.66 µU/ml, P = 0.032) were significantly lower in the vitamin K group compared to placebo. Additionally, triglycerides (TG) (144.94 ± 50.7 vs. 172.8 ± 101.5 mg/dl, P = 0.031) and very low-density lipoproteins (VLDL) levels (28.9 ± 9.88 vs. 34.6 ± 20.30 mg/dl, P = 0.027) decreased significantly in the vitamin K group after 24 weeks compared to baseline. Moreover, more patients in the vitamin K group (35.6%) had their antidiabetic medication doses reduced after 24 weeks compared to placebo (13.3%, P = 0.029). Conclusion: Vitamin K4 supplementation for 24 weeks is capable of improving insulin resistance and TG levels in individuals with type 2 diabetes. In addition, the improvement in insulin resistance was reflected in the decrease in antidiabetic medication doses. However, it did not affect fasting plasma glucose (FPG) or glycated haemoglobin (HbA1c). Trial registration: The study was registered on clinicaltrials.gov with ID: NCT04285450.